




# Perinatal Substance Use Disorders

Connie Guille, MD,




# Overview

- Screening for Perinatal SUDs
- MOUD for OUD




# Pregnancy-Associated Deaths Due to Drugs, Suicide, and Homicide in the United States, 2010–2019 (n=11,792)



- 22.2% of all Maternal Deaths are due to:
  - Drugs (11.4%)
  - Suicide (5.4%)
  - Homicide (5.4%)
- 2010-2019
  - Drug-related deaths increased 190%
  - Suicide increased 30%
  - Homicide increased 63%


# US Trends in Drug Overdose Mortality Among Pregnant and Postpartum Persons, 2017-2020

Figure. Pregnancy-Associated Drug Overdose Mortality



Bruzelius E, Martins SS. US Trends in Drug Overdose Mortality Among Pregnant and Postpartum Persons, 2017-2020. *JAMA*. 2022;328(21):2159–2161. doi:10.1001/jama.2022.17045

# Prevalence of Opioid Use Disorder in Pregnancy



Per 1,000 Delivery Hospitalizations in US 1999-2014

Haight SC, Ko JY, Tong VT, Bohm MK, Callaghan WM. Opioid Use Disorder Documented at Delivery Hospitalization — United States, 1999–2014. MMWR Morb Mortal Wkly Rep 2018;67:845–849.

# Screening for Substance Use

- Routine screening with validated questionnaires (VQ) (i.e. **4 P's or 4 P's Plus** ©, NIDA Quick Screen, CRAFTT (adolescents) should be performed on all pregnant persons at least once. (Universal screening reduces biases age, race, ethnicity, or socioeconomic status).
- Validated questionnaires (VQ) are superior to urine drug screening (UDS) for detection of specific substance use or absence of use.
- South Carolina SBIRT Screening Tool Pregnant & Postpartum Individuals

[https://www.scdhhs.gov/sites/default/files/SBIRT%20Universal%20Screening%20Tool%20June%202015\\_1.pdf](https://www.scdhhs.gov/sites/default/files/SBIRT%20Universal%20Screening%20Tool%20June%202015_1.pdf)

# Limitations of UDS for screening and detecting use

- UDS do not testing for alcohol or tobacco.
- Drugs metabolize out of the urine in relatively short amounts of time.
  - UDS only detects use (other than MJ) in past 2-3 days.
- Most tests do not include semi or fully synthetic opioids (i.e., prescription opioids, fentanyl)
- Lots of false positives with qualitative (yes/no) tests
- Provider knowledge gaps about the need for:
  - Confirmatory testing with +UDS qualitative (yes) result
  - Informed consent for testing, and patient's right to refuse testing
- Mandatory reporting and criminalization of use during pregnancy
- UDS is not mandatory for assessment of SUD during pregnancy (ACOG)

# UDS Window of Detection 2-3 Days

<b>Length of Time Drugs of Abuse Can Be Detected in Urine</b>	<b>Drug</b>	<b>Time</b>
Alcohol		7-12 h
Amphetamine		48 h
Methamphetamine		48 h
Barbiturate		
Short-acting (eg, pentobarbital)		24 h
Long-acting (eg, phenobarbital)		3 wk
Benzodiazepine		
Short-acting (eg, lorazepam)		3 d
Long-acting (eg, diazepam)		30 d
Cocaine metabolites		2-4 d
Marijuana		
Single use		3 d
Moderate use (4 times/wk)		5-7 d
Daily use		10-15 d
Long-term heavy smoker		30 d
Opioids		
Codeine		48 h
Heroin (detected as morphine)		48 h
Hydromorphone		2-4 d
Methadone		3 d
Morphine		48-72 h
Oxycodone		2-4 d
Propoxyphene		6-48 h
Phencyclidine		8 d

Fentanyl 24-72 hours



# Commonly Used Obstetric Medications That May Cause False Positives on UDS

UDS RESULT	Amphetamine/ Methamphetamine	Benzodiazepine	Barbiturate	Phencyclidine (PCP)	Opiates
<b>MEDICATION</b>					
Bupropion	X				
Dextromethorphan				X	
Diphenhydramine					X
Doxylamine					X
Fioricet/Fiorinal			X		
Labetalol & Methyldopa	X				
Metformin	X				
Phenylephrine	X				
Promethazine	X				
Quetiapine (≥ 125 mg)					X
Sertraline (>150 mg)		X			
Tramadol				X	X
Trazadone	X				
Venlafaxine				X	
Verapamil					X

# UDS Qualitative (Yes/No)

Many opioids are not part of standard EIA so may need to order specifically (bup/nor-bup)

## IF UDS IS + FOR:

## SPECIFIC ENOUGH TO MAKE CLINICAL DECISIONS WITHOUT CONFIRMATORY TEST?

AMPHETAMINES

NO send \*GC/MS

BARBITURATES

YES

BENZODIAZEPINES

YES

CANNABINOIDS

YES

COCAINE

YES

METHADONE

YES

OPIATES

NO send \*GC/MS

OXYCODONE

NO send \*GC/MS

\*GC/MS: Confirmatory: –Gas Chromatography/ Mass Spectrometry

Pregnancy/Postpartum + UDS  
Qualitative Yes- Send for GC/MS

# When is a UDS useful and how is the test obtained?

UDS is useful in circumstances where:

- Maternal health is impacted (e.g., emergency, loss of consciousness, impaired or altered mental status)
- Patient requests UDS
- Starting MOUD (not always needed especially if delays care or creates punitive consequences)
- Suspect diversion of Suboxone, or confirm patient is taking medication
  - Order test for **norbuprenorphine**

# How is UDS test obtained?

- Informed consent is ethically obligated and recommended by ACOG, Amnesty International, ASAM, WHO, SAMHSA.
- Written consent is preferred during pregnancy due to higher stakes and unintended consequences.
- If anything is positive, send for confirmatory testing due to higher stakes and unintended consequences.

# UDS Practice

- Standardized protocol
  - Biased screening disproportionately affects low-income birthing people of color, particularly African Americans.
- Formal informed consent process
- Communicate and document clear utility for the test
  - Reason(s) for ordering UDS (e.g., signs and symptoms consistent with intoxication, withdrawal, or altered mental status, patient request etc.)
  - Documents verbal or written informed consent or reason for absence of consent (e.g., emergency, loss of consciousness)
- Wait for confirmatory test before assuming use or changing patient care.
- Review chart for possible cross-reacting medications prescribed and OTC.
- Pay attention to false positive potential prior to counseling patients or calling CPS.